Articles tagged with Hiv Vaccines
A novel mRNA-based HIV vaccine has been shown to be safe and elicit desired immune responses in mice and non-human primates. The vaccine prompted a 79% lower per-exposure risk of infection by simian-human immunodeficiency virus compared to unvaccinated animals.
Researchers have designed a new nanoparticle adjuvant that significantly improves antibody production following vaccination against HIV, diphtheria, and influenza. The adjuvant speeds up lymph flow to lymph nodes, helps antigens reach B cells before breaking down, and activates inflammatory cytokines for a stronger response.
Scientists at La Jolla Institute for Immunology and MIT have discovered a new adjuvant called SMNP, which combines saponin and TLR agonist to boost the protective power of vaccines. The study found that SMNP triggers a strong immune response in mice, promoting lymphatic drainage and activating multiple parts of the immune system.
A new study reveals that memory T helper cells can work with memory B cells to effectively defend the body against chronic viruses. This finding has direct relevance to developing new vaccines for HIV and hepatitis C, as it suggests a more sustained immune response.
Researchers discovered that a lower dose of the first shot, followed by a full-dose booster, significantly improved SARS-CoV-2 vaccine potency in mice. This approach, which involves an extended prime-boost interval, may lead to more robust and durable immune responses.
A recent study from Scripps Research found that proof-of-concept HIV vaccines generate off-target antibodies that degrade the vaccine's payload, hindering protection. The research provides critical insights for improving HIV subunit trimer vaccines and offers a promising avenue for design improvements.
Researchers at Duke University Medical Center discovered a new type of anti-glycan antibody that can neutralize HIV by targeting its sugar coating. This breakthrough points to a novel vaccine strategy that could also be used against SARS-CoV-2 and fungal pathogens.
The Novavax Covid-19 vaccine demonstrated an overall efficacy of 49% in the initial analysis and 60% among healthy adults without HIV, providing protection against mild disease caused by the B.1.351 variant prevalent in South Africa. The updated analysis showed 100% protection against severe Covid-19 due to the B.1.351 variant.
Researchers from Oregon Health & Science University have finally understood how their cytomegalovirus-based vaccine works in monkeys, generating a unique type of immune response to fight off SIV. The breakthrough sheds light on the design of future CMV-based vaccines and offers new hope against HIV.
Researchers propose genomic sieve analysis to examine COVID-19 vaccine breakthrough infections, revealing viral mutations that evade the immune response. The technique predicts potential mechanisms of vaccine protection and future vaccine resistance.
A Phase 1 trial evaluating Army-developed ALF adjuvants in HIV-1 vaccine regimens aims to improve immune responses. The study will compare different adjuvants and inform a promising vaccine strategy for stronger, more durable immune responses.
A novel algorithm, Epigraph, has been used to create a broadly reactive influenza vaccine for swine flu and may also be applicable to developing a pan-coronavirus vaccine. The immune responses to the vaccine showed promising breadth against diverse viral variants.
A phase 1 clinical trial testing a novel vaccine approach to prevent HIV has produced promising results, stimulating the production of rare immune cells needed to generate broadly neutralizing antibodies. The targeted response was detected in 97 percent of participants who received the vaccine.
A new intranasal influenza vaccine demonstrated a durable immune response in a Phase 1 study, producing higher antibody levels compared to oral vaccination. The vaccine induced mucosal immunity and neutralizing antibodies at 26 weeks after vaccination, with sustained protection lasting up to five years.
Researchers at Scripps Research successfully generated antibodies against multiple strains of HIV in mice using genetically engineered immune cells. The approach shows promise for preventing new HIV infections and potentially offering a functional cure for those with HIV/AIDS.
Researchers at the University of Chicago have discovered a new way to limit inflammation from adjuvants by adding a molecule that disrupts certain pathways in cells. This approach increases protective response against viruses and could lead to a new vaccine design for SARS-CoV-2, HIV, and other diseases.
Investigating potential adverse effects and antibody-dependent enhancement is crucial for vaccine development. Comprehensive safety tests are necessary before widespread implementation.
Researchers developed a new HIV vaccine that combines neutralizing antibodies with cellular immunity to provide more effective protection. The vaccine showed promising results in preventing infection and lasting for over a year after vaccination.
A new type of vaccination has been shown to substantially enhance and sustain protection from HIV in monkeys, with a two-armed approach stimulating both serum and cellular immunity. The findings have broad implications for immunologists pursuing vaccines for other diseases, particularly those caused by coronaviruses.
A Phase 2b/3 study in South Africa found that an investigational prime-boost vaccine regimen did not prevent HIV, but participants were safe. Researchers are continuing to explore other approaches to a safe and effective HIV vaccine.
Researchers found that ART may not restore immune protection from childhood vaccinations and infections prior to HIV infection. This could leave patients susceptible to chronic diseases and inflammation, potentially shortening their lifespan.
Researchers at UC Davis discovered that rectal microbes can impact HIV vaccine efficacy, with Lactobacillus supplements boosting antibody production and Prevotella bacteria hindering immune responses. The study suggests targeting specific gut bacteria may improve vaccine performance.
Creating too many Th1 cells at mucosal sites compromises effective vaccine protection against HIV. Researchers have identified a key balance needed to stimulate the immune response without increasing susceptibility to the virus.
The experimental HIV vaccine developed by Scripps Research and IAVI successfully elicited broadly neutralizing antibodies to at least two vulnerable sites on HIV. The test results suggest that researchers are one step closer to developing an effective HIV vaccine, a major goal of medical science.
Research reveals that activated T helper cells can hinder HIV vaccine efficacy, as they migrate to mucosal tissues and express coreceptors that facilitate viral entry. This discovery highlights the need for careful consideration of T cell responses in vaccine development.
A new HIV vaccine strategy has been successfully demonstrated in proof-of-principle tests, targeting young immune cells and showing promise against the flu, dengue, malaria, and hepatitis C. The approach stimulates broadly neutralizing antibodies capable of neutralizing multiple strains of the virus.
A recent HVTN study found that antibody-mediated and cellular-mediated immune responses correlate with a decrease in HIV transmission. The study demonstrated that measuring both types of immune responses can predict the transmission of HIV, providing new insights into potential correlates of protection (CoP).
A study by HVTN 105 demonstrated that DNA (DNA-HIV-PT123) and protein (AIDSVAX B/E) combination vaccine regimens induced high magnitude and long-lasting binding antibody responses. The findings showed more rapid potentially protective immune responses when the vaccine regimens were co-administered.
The study found significant cellular and antibody responses in South African participants, with higher CD4+ T cell response rates and stronger cross-clade antibody responses compared to Thai participants. The results suggest that the RV144/Thai vaccine regimen can induce a broader immune response across different HIV clades.
The RV144 vaccine has shown promising results with a new study indicating it may provide protection against multiple strains of HIV. Researchers discovered that the vaccine elicited stronger immune responses, particularly in men, and was well-tolerated, suggesting potential long-term efficacy.
A new study identified a transcriptional signature in B cells that correlates with protection from SIV or HIV infection in five independent trials of HIV-1 vaccine candidates. The gene expression signature was found to be associated with the only human HIV vaccine trial that previously showed modest efficacy, RV144.
Researchers developed an implantable microneedle skin patch containing an HIV subunit vaccine, which led to sustained intradermal vaccine release and improved antibody responses in mice. The study suggests that microneedle patches may enhance vaccine effectiveness.
A new viral HIV vaccine has successfully protected rhesus macaques from high-dose SIVmac239 challenges, a notoriously difficult-to-defeat strain. The vaccine uses a gene-therapy inspired approach and durable protection is achieved with a single inoculation.
Mount Sinai researchers have developed a novel vaccine consisting of DNA and recombinant proteins, which was tested in monkeys and induced antibodies similar to those associated with protection from HIV. The vaccine targets the V1V2 loop of the gp120 envelope protein and showed strong protective effects against HIV infection.
A weakened form of a CMV-based vaccine has been shown to provide similar protection against SIV in 59% of vaccinated rhesus macaques, with long-lasting immunity observed. The vaccine's attenuated version is key for human testing due to safety concerns.
The NIH is launching a Phase 3 HIV vaccine efficacy trial called Mosaico, which will assess the safety and effectiveness of an investigational vaccine regimen designed to prevent HIV acquisition among men who have sex with men and transgender people. The trial will enroll 3,800 participants in North America, South America, and Europe.
A seven-year NIH grant will support refinement and manufacturing of novel vaccine candidates designed to induce broadly neutralizing antibodies capable of disarming numerous HIV strains. The goal is to develop a vaccine that can halt the epidemic, despite current challenges posed by the virus's ability to rapidly evolve.
A protein from Simian Immunodeficiency Virus (SIV) has shown promise as a potential component of an HIV vaccine, eliciting antibodies that neutralize infection against multiple HIV strains. The study uses SIV Env proteins to stimulate the immune system to produce protective antibodies.
Scientists at La Jolla Institute for Immunology developed a new HIV vaccine delivery strategy that enhances the protective immune response by slowly releasing vaccine doses. This approach, called escalating dose strategy, leads to stronger and more neutralizing antibodies against the virus.
Researchers developed a novel recombinant vaccine called NIPRAB that shows strong immunization against Nipah virus in animal models. The live vaccine is safe in mice, eliciting a strong antibodies response and reacting to similar viruses like Hendra and Rabies.
A Rutgers study found that over 58% of minority gay and bisexual men have HPV infection, with only 18% having received the full dose of the HPV vaccine. The study highlights the need for outreach to at-risk populations as the HPV vaccination uptake is incredibly low in the US.
A new nanoparticle vaccine candidate has been designed to elicit potent neutralizing antibodies against respiratory syncytial virus (RSV), a leading cause of infant mortality worldwide. The vaccine's computer-designed nanoparticle platform holds promise for applying to other diseases, including flu and HIV.
Researchers at Duke University Medical Center have made a breakthrough in understanding how HIV antibodies adapt to viral changes, identifying a crucial mutation that enables them to target diverse virus strains. This finding has significant implications for developing effective HIV vaccines.
A new malaria vaccine using a cytomegalovirus-based platform has shown promising results, reducing the parasite's release by 75-80% in infected rhesus macaques. The vaccine could offer lifelong protection against malaria, a disease that claims hundreds of millions of lives each year.
A new study published in Immunity shows that an experimental HIV vaccine protects rhesus macaques from infection by inducing neutralizing antibodies against a Tier 2 virus. The vaccine strategy, developed over two decades, aims to train the immune system to recognize and attack vulnerable areas on the HIV envelope protein.
A team of researchers at Duke University Medical Center has identified a shortcut to recreate a critical HIV antibody that neutralizes the virus. By understanding the maturation pathway of this antibody, they found a strategic detour around a previous obstacle, enabling the development of more effective vaccines.
A new candidate HIV vaccine from Scripps Research stimulates a powerful anti-HIV antibody response in animal tests, overcoming technical hurdles that stymied previous vaccine efforts. The vaccine strategy is based on the HIV envelope protein, Env, and uses a simple method to stabilize Env proteins in the desired shape.
Researchers identified seven specific HPV types linked to increased risk of HIV infection in a study published in PLOS ONE. The study found that individuals with any HPV type, multiple HPV types, or high-risk HPV were more likely to test positive for HIV.
Scientists at The Wistar Institute developed a novel strategy for delivering complex anti-HIV immunoadhesins using synthetic DNA technology, achieving robust and long-term in vivo expression. This breakthrough enables the production of functional eCD4-Ig immunoadhesin with enhanced potency.
Scientists have developed a faster way to analyze the outcome of experimental vaccines against HIV and other pathogens. The new system lets researchers quickly assess the full spectrum of antibodies produced in an individual's response to a pathogen or vaccine.
A research group led by Professor Andrei Kozlov has identified a key genetic bottleneck effect that could help design an HIV vaccine. By analyzing blood samples from injecting drug users with early stages of HIV infection, scientists discovered that all viruses share a common ancestor.
A new HIV vaccine candidate has triggered desired immune responses in humans and monkeys, demonstrating robust protection against infection. The 'mosaic' vaccine contains a patchwork of genetic sequences found among various HIV strains, providing broad protection against the many strains prevalent worldwide.
A new HIV vaccine candidate has been shown to be safe and induce an immune response in both healthy adults and rhesus monkeys. The vaccine protected against infection with an HIV-like virus in monkeys and showed comparable results to those seen in humans, paving the way for a phase 2b clinical efficacy trial.
A new experimental vaccine regimen has been developed using a vulnerable site on HIV to induce antibodies that can neutralize multiple strains of the virus. In tests with mice, guinea pigs, and monkeys, the vaccine elicited antibodies that neutralized up to 31% of viruses from a globally representative panel of 208 HIV strains.
A Phase 3 clinical trial demonstrates the safety and efficacy of IMVAMUNE, a non-replicating smallpox vaccine. The study showed twofold higher neutralizing antibodies compared to ACAM2000, a statistically superior immune response.
Researchers have made significant advancements in HIV vaccine production, using robotics and gene editing technology to improve yields and reduce costs. The new methods could lead to more effective vaccines with higher efficacy rates, potentially increasing protection against the AIDS virus.
A new TB vaccine has shown promising results in a study of nonhuman primates, providing 41% protection and reducing overall disease by 68%. The vaccine uses a weakened form of a common Herpes virus to create high immunity against the pathogen.
A new population-based model has been developed to track new HIV infections with greater accuracy, enabling researchers to better target prevention strategies and evaluate interventions. The tool uses biomarkers to identify recent infections, reducing false classifications and costs for studies.
A randomized clinical trial found no benefit for a therapeutic HIV vaccine in suppressing viral infection, but provided valuable insights for future cure efforts. Four people in the placebo group exhibited spontaneous HIV suppression, exceeding expected rates among the general population.
The NIH has launched a Phase 2b proof-of-concept study called Imbokodo to assess the safety and efficacy of an experimental HIV vaccine regimen. The study aims to enroll 2,600 HIV-negative women in sub-Saharan Africa and will test the quadrivalent mosaic vaccine against placebo.